Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer
November 11, 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer - Related patent recently granted and...
Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer
November 11, 2020 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer - Related patent recently granted and...
Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer
October 07, 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer Stevenage, UK 7 October 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing...
Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer
October 07, 2020 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer Stevenage, UK 7 October 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing...
Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer
June 23, 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer Stevenage, UK 23 June 2020 – Achilles Therapeutics (“Achilles”), a clinical stage...
Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer
June 23, 2020 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer Stevenage, UK 23 June 2020 – Achilles Therapeutics (“Achilles”), a clinical stage...
Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma
May 29, 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens Stevenage, UK 29 May...
Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma
May 29, 2020 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens Stevenage, UK 29 May...
Achilles Therapeutics announces formation of Scientific Advisory Board
May 13, 2020 07:00 ET
|
Achilles Therapeutics
Achilles Therapeutics announces formation of Scientific Advisory Board - World-leading experts in oncology, immunology and R&D will advise the Company as it advances pipeline of pioneering cancer...
Achilles Therapeutics announces formation of Scientific Advisory Board
May 13, 2020 02:00 ET
|
Achilles Therapeutics
Achilles Therapeutics announces formation of Scientific Advisory Board - World-leading experts in oncology, immunology and R&D will advise the Company as it advances pipeline of pioneering cancer...